Pelage Pharmaceuticals
LOS ANGELES, CA · Biotechnology, Healthcare · 10 employees
Pelage Pharmaceuticals is a clinical-stage regenerative medicine company developing first-in-class treatments for hair loss. With a focus on stem cell biology and metabolism, Pelage is advancing a new class of treatments designed to reactivate dormant hair follicle stem cells and restore the body’s ability to naturally grow hair. Its lead program, PP405, is currently in Phase 2a clinical trials. T
Funding history
- Funding Round — $120.0M — Nov 2025
- Series series b — $120.0M — Oct 2025
- Funding Round — $14.0M — Aug 2024
- Funding Round — $14.0M — Aug 2024
- Series series a — $16.8M — Feb 2024
Recent signals
- Feb 23, 2026: Pelage Pharmaceuticals Appoints Nathan Wheeler as Chief Operating Officer
- Nov 24, 2025: Raised $120.0M
- Oct 15, 2025: Raised $120.0M in Series series b
- Aug 23, 2024: Raised $14.0M
- Aug 13, 2024: Raised $14.0M
- Feb 27, 2024: Raised $16.8M in Series series a
- Jun 28, 2023: Raised $16.7M
See plans & pricing → Track Pelage Pharmaceuticals’s funding, hiring, and signals — with verified contacts — on Fundz.